Mesothelin-targeted chimeric antigen receptors and uses thereof

US10633441B2 · kind B2 · utility

Assignees

• Memorial Sloan Kettering Cancer Center · US
• The U.S.A., as represented by The Secretary, Department of Health and Human Services · US

Inventors

• Prasad S. Adusumilli · Edison, US
• Michel Sadelain · New York, US
• Dimiter S. Dimitrov · Frederick, US
• Yang Feng · Frederick, US

Key dates

• Filing date: Dec 2, 2016
• Grant date: Apr 28, 2020
• Expiry date: Dec 2, 2036

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/03
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The presently disclosed subject matter provides for methods and compositions for enhancing the immune response toward cancers and pathogens. It relates to chimeric antigen receptors (CARs) that specifically target human mesothelin, and immunoresponsive cells comprising such CARs. The presently disclosed mesothelin-targeted CARs have enhanced immune-activating properties, including anti-tumor activity.